Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy


Altundag K., Aksoy S., Gullu I., Altundag O., Ozyar E., Yalcin S., ...Daha Fazla

MEDICAL ONCOLOGY, cilt.21, sa.3, ss.211-215, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 3
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1385/mo:21:3:211
  • Dergi Adı: MEDICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.211-215
  • Anahtar Kelimeler: nasopharyngeal carcinoma, ifosfamide, adriamycin, chemotherapy, recurrent, PHASE-II TRIAL, METASTATIC UNDIFFERENTIATED CARCINOMA, 5-FLUOROURACIL, GEMCITABINE, EPIRUBICIN, SURVIVAL, CANCER
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

This study evaluated the efficacy and toxicity of ifosfamide and doxorubicin chemotherapy regimen in Turkish patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) previously treated with platinum-based chemotherapy. Twenty-one patients with recurrent or metastatic NPC previously treated with platinum-based chemotherapy as adjuvant or palliative treatments who received ifosfamide 2500 mg/m(2) d 1-3, mesna 2500 mg/m(2) d 1-3, doxorubicin 60 mg/m(2) d 1, repeated every 21 d was retrospectively analyzed. Patients received a median number of three cycles of ifosfamide-doxorubicin (range: 1-6). Seven patients (33.3%) achieved partial response and no patient achieved complete response. Six (28.5%) had stable disease, whereas three (18.75%) had progressive disease. The median time to progression was 7.0 mo. Ifosfamide-doxorubicin regimen is an effective salvage regimen in patients with recurrent and metastatic NPC.